secwatch.observer — SEC 8-K summary
======================================

Issuer:     OptimizeRx Corp (OPRX)
CIK:        0001448431
Form:       8-K/A
Filed at:   2022-08-10T23:59:59+00:00
Accession:  0001213900-22-046091
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OptimizeRx Q2 revenue up 3% to $14M, GAAP net loss of $3.9M, cuts FY 2022 outlook
--------------------------------------------------------------------------------

- GAAP net loss of $3.9M ($0.21/sh) vs prior-year net income of $0.4M ($0.02/sh).
- Non-GAAP net income of $0.7M ($0.04/sh) down from $1.8M ($0.10/sh) a year ago.
- Gross margin improved to 64% from 59%; revenue of $14.0M, +3% YoY.
- FY 2022 revenue guidance lowered to $62-68M (1-11% growth); gross margin 59-62%.
- Share repurchase program authorized up to $20M; 232,745 shares bought at avg $23.02.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1448431/000121390022046091/0001213900-22-046091-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1448431/000121390022046091/ea164114-8ka1_optimize.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-046091

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer